Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Recombinant Poultry Virus Selectively Kills Human Prostate Cancer Cells

By BiotechDaily International staff writers
Posted on 05 Mar 2013
Print article
A recombinant form of the Newcastle disease virus (NDV) that replicates in humans only in the presence of prostate specific antigen (PSA) was found to kill prostate cancer cells, including hormone resistant cells, without damaging normal tissues.

Newcastle disease is a contagious bird disease affecting many domestic and wild avian species. The virus has a negative-sense, single-stranded genome that codes for a RNA-directed RNA polymerase, hemagglutinin-neuraminidase protein, fusion (F) protein, matrix protein, phosphoprotein, and nucleoprotein in the 5' to 3' direction. Its effects are most notable in domestic poultry due to their high susceptibility and the potential for severe impacts of an epizootic on the poultry industries. Exposure of humans to infected birds can cause mild conjunctivitis and influenza-like symptoms, but NDV otherwise poses no hazard to human health. Interest in the use of NDV as an anticancer agent has arisen from the ability of NDV to selectively kill human tumor cells with limited toxicity to normal cells. However, systemically delivered NDV fails to reach solid tumors in therapeutic concentration and also spreads poorly within the tumors due to barriers including complement, innate immunity, and extracellular matrix.

Investigators at the Virginia Polytechnic Institute (Blacksburg, USA) created a novel recombinant form of NDV in which the F protein was cleavable exclusively by human PSA.

They reported in the January 23, 2013, online edition of the Journal of Virology that the recombinant NDV replicated efficiently and specifically in prostate cancer (CaP) cells and three-dimensional prostaspheres but failed to replicate in the absence of PSA. Furthermore, PSA-cleavable recombinant NDV caused specific lysis of androgen independent and androgen responsive/nonresponsive CaP cells and prostaspheres. PSA-cleavable NDV failed to replicate in chicken embryos, indicating no pathogenicity to chickens.

"Retargeted Newcastle disease virus has major potential advantages over other cancer therapies," said senior author Dr. Subbiah Elankumaran, associate professor of virology at Virginia Polytechnic Institute. "First, its specificity for prostate cancer cells means it would not attack normal cells, thereby avoiding the various unpleasant side effects of conventional chemotherapies. In previous clinical trials, even with extremely large doses of naturally occurring strains, only mild flu-like symptoms were seen in cancer patients. Second, it would provide a new treatment for hormone-refractory patients, without the side effects of testosterone suppression that result from hormonal treatments."

Related Links:
Virginia Polytechnic Institute



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.